Kolltan Pharmaceuticals Inc., of New Haven, Conn., presented preclinical data from a study evaluating KTN0158 in dogs with spontaneous mast cell tumors. Read More
Corcept Therapeutics Inc., of Menlo Park, Calif., reported a third quarter GAAP net loss of $600,000, down from $6 million in the third quarter of 2014. Non-GAAP net income for the period increased to $1.6 million, compared to a non-GAAP net loss of $3.9 million in the third quarter of 2014. Read More
Tracon Pharmaceuticals Inc., of San Diego, reported updated data from a phase Ib trial combining TRC105 with Inlyta (axitinib, Pfizer Inc.) in patients with advanced or metastatic renal cell carcinoma at the Kidney Cancer Association meeting in Miami. Read More
A team from Genentech Inc. has developed an antibody-antibiotic conjugate (AAC) that was able to fight intracellular Staphylococcus aureus in mice, offering hope for the development of a therapeutic strategy against relapsing infections. Read More
Cyteir Therapeutics Inc., of Cambridge, Mass., closed a $5.5 million series A financing that included participation from a syndicate of private investors and Celgene Corp., of Summit, N.J. Read More
The needs of the many outweighing the needs of the one might seem the acme of logic, at least for a Vulcan. For humans, it's not so simple, and it's only one of several thorny problems industry, government and society must resolve to establish clear guidance to provide dying patients with compassionate use access to experimental drugs. Read More
With the hyperkalemia (HK) space hotter after Astrazeneca plc's $2.7 billion takeover of ZS Pharma Inc. to get the approval-ready ZS-9, eyes of handicappers turned to long-term safety data due at a scientific meeting over the weekend. Read More
HONG KONG – In back-to-back deals involving a total of $735 million in up-front cash, French pharma major Sanofi SA is collecting more diabetes drugs for its pipeline, aiming to mitigate the impact on its diabetes business, which has seen a 6.6 percent decline in the global market. Read More
Even though it is sponsored by three organizations, the joint Molecular Targets meeting of the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) is smaller than the annual meetings of the big organizations – including that of AACR itself. Read More
LONDON – The EMA is planning to add a new Priority Medicines (PRIME) designation to the various schemes it operates to accelerate access to innovation. Read More
BOGOTA, Colombia – Regulators in Colombia have fined six pharmaceutical companies for breaching price caps set by the National Board of Prices of Drugs. Among the companies targeted are Novartis AG and Sanofi-Aventis. Read More
